Background illustration for clinical trials search

Multiple Myeloma Clinical Trials

Browse 1,243 multiple myeloma clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1

Horizon Two: HR NDMM (MMRC-100)

for
High Risk Newly Diagnosed Multiple Myeloma
Location: New York NY, Chapel Hill NC, Detroit MI, Atlanta GA,
Sponsor: Multiple Myeloma Research Consortium

Sex: All

Age: 18+

Code: NCT07053436

Phase2, Recruiting

Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma

for
Relapse Multiple Myeloma, Refractory Multiple Myeloma
Location: Madison WI
Sponsor: Natalie Callander

Sex: All

Age: 18+

Code: NCT07479979

Phase1, Phase2, Recruiting

A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma

for
Multiple Myeloma, Relapse Multiple Myeloma,
Location: Boston MA
Sponsor: David Avigan

Sex: All

Age: 18+

Code: NCT06799026

Phase1, Recruiting

Pre-malignant States to Hematologic Malignancies in Firefighters

for
Clonal Hematopoiesis of Indeterminate Potential,
Location: Charlotte NC
Sponsor: Wake Forest University Health Sciences

Sex: All

Age: 40 - 49

Code: NCT06870760

Recruiting

Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma

for
Multiple Myeloma, Post Stem Cell Transplant
Location: Palo Alto CA
Sponsor: Stanford University

Sex: All

Age: 18+

Code: NCT06461988

Phase2, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

for
Multiple Myeloma Refractory, Multiple Myeloma in Relapse
Location: Boston MA, Hackensack NJ, New Brunswick NJ,
Sponsor: CellCentric Ltd.

Sex: All

Age: 18+

Code: NCT07096778

Phase2, Recruiting

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

for
Multiple Myeloma
Location: Halifax, Commack NY, Uniondale NY, Harrison NY,
Sponsor: Pfizer

Sex: All

Age: 18+

Code: NCT05020236

Phase3, Recruiting

A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

for
Relapsed and/or Refractory Multiple Myeloma (RRMM)
Location: New York NY, Columbus OH, Atlanta GA, Houston TX,
Sponsor: Regeneron Pharmaceuticals

Sex: All

Age: 18+

Code: NCT07222761

Phase3, Recruiting

Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)

for
Multiple Myeloma
Location: New Haven CT
Sponsor: Noffar Bar

Sex: All

Age: 18+

Code: NCT06993675

Phase2, Recruiting

Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma

for
Multiple Myeloma, Newly Diagnosed, Multiple Myeloma (MM)
Location: Norfolk VA, Chapel Hill NC, Columbus OH, Birmingham AL,
Sponsor: SCRI Development Innovations, LLC

Sex: All

Age: 19+

Code: NCT06974786

Phase2, Recruiting

Addressing Social Determinants of Health Among Metro Detroit Cancer Survivors

for
Cancer, Cancer Survivors, Gastrointestinal Cancers,
Location: Detroit MI
Sponsor: Barbara Ann Karmanos Cancer Institute

Sex: All

Age: 18+

Code: NCT06908629

Recruiting

A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments

for
Multiple Myeloma
Location: Boston MA, Wilson NC, Chapel Hill NC, Pembroke Pines FL,
Sponsor: GlaxoSmithKline

Sex: All

Age: 18+

Code: NCT05714839

Phase1, Phase2, Recruiting

PET/MR Scan With [68Ga]Ga-PentixaFor (CXCR4) vs Standard of Care (SOC) for Initial Staging and Follow up in Multiple Myeloma (MM)

for
Multiple Myeloma
Location: Toronto
Sponsor: University Health Network, Toronto

Sex: All

Age: 18+

Code: NCT06871176

Recruiting

A Study of Dara-RVd and Teclistamab-RVd in People With Multiple Myeloma

for
Multiple Myeloma
Location: Commack NY, Uniondale NY, Harrison NY, New York NY,
Sponsor: Memorial Sloan Kettering Cancer Center

Sex: All

Age: 18+

Code: NCT07099391

Phase1, Phase2, Recruiting

Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse

for
Multiple Myeloma
Location: Miami FL
Sponsor: Dickran Kazandjian, MD

Sex: All

Age: 0+

Code: NCT06910124

Phase2, Recruiting

A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)

for
Multiple Myeloma
Location: New York NY, Charlottesville VA, Tampa FL, Atlanta GA,
Sponsor: AstraZeneca

Sex: All

Age: 18+

Code: NCT07073547

Phase1, Recruiting

Integrated Cancer Repository for Cancer Research

for
Pancreatic Cancer, Thyroid Cancer, Lung Cancer,
Location: Manchester CT, Holyoke MA, Glens Falls NY, Utica NY,
Sponsor: University of Nebraska

Sex: All

Age: 19 - 70+

Code: NCT02012699

Recruiting

A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

for
Multiple Myeloma, Newly Diagnosed Multiple Myeloma
Location: Saint John, Portland ME, Providence RI, Worcester MA,
Sponsor: GlaxoSmithKline

Sex: All

Age: 18+

Code: NCT06679101

Phase3, Recruiting

Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma

for
Multiple Myeloma, Refractory Multiple Myeloma,
Location: San Francisco CA
Sponsor: Alfred Chung, MD

Sex: All

Age: 18+

Code: NCT06348108

Phase1, Recruiting

Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

for
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Location: Rochester MN
Sponsor: Mayo Clinic

Sex: All

Age: 18+

Code: NCT06940297

Phase2, Recruiting